Dr Connor Blair

  • Research Associate (Institute of Cardiovascular & Medical Sciences)

Biography

  • BSc (Hons) Neuroscience
  • MRes in Biomedical Sciences
  • PhD  Molecular Pharmacology

Research interests

Discovering and developing proprietary cell-penetrating peptide modulators of pathological protein-protein interactions as novel therapeutics in Oncology.

Publications

List by: Type | Date

Jump to: 2021 | 2020 | 2019
Number of items: 6.

2021

Mahindra, A. et al. (2021) Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 16(11), e0260283. (doi: 10.1371/journal.pone.0260283) (PMID:34793553) (PMCID:PMC8601423)

Morgan, D. C. et al. (2021) Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalisation. Peptide Science, 113(4), e24217. (doi: 10.1002/pep2.24217) (PMID:33615115) (PMCID:PMC7883042)

2020

Ling, J., Blair, C. M. and Baillie, G. S. (2020) Fibrin Breakdown Assay. Bio-Protocol, 10(8), e3585. (doi: 10.21769/BioProtoc.3585)

Blair, C. M., Ling, J. and Baillie, G. S. (2020) Measuring cAMP specific phosphodiesterase activity: a two-step radioassay. Bio-Protocol, 10(7), e3581. (doi: 10.21769/BioProtoc.3581) (PMID:33659551) (PMCID:PMC7842805)

2019

Blair, C. M. and Baillie, G. S. (2019) Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes. Biochemical Society Transactions, 47(5), pp. 1405-1414. (doi: 10.1042/BST20190252) (PMID:31506329)

Blair, C. M., Walsh, N., Littman, B. H., Marcoux, F. W. and Baillie, G. S. (2019) Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf. BMC Cancer, 19, 266. (doi: 10.1186/s12885-019-5489-4) (PMID:30909892) (PMCID:PMC6434832)

This list was generated on Tue Dec 7 08:26:11 2021 GMT.
Jump to: Articles
Number of items: 6.

Articles

Mahindra, A. et al. (2021) Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 16(11), e0260283. (doi: 10.1371/journal.pone.0260283) (PMID:34793553) (PMCID:PMC8601423)

Morgan, D. C. et al. (2021) Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalisation. Peptide Science, 113(4), e24217. (doi: 10.1002/pep2.24217) (PMID:33615115) (PMCID:PMC7883042)

Ling, J., Blair, C. M. and Baillie, G. S. (2020) Fibrin Breakdown Assay. Bio-Protocol, 10(8), e3585. (doi: 10.21769/BioProtoc.3585)

Blair, C. M., Ling, J. and Baillie, G. S. (2020) Measuring cAMP specific phosphodiesterase activity: a two-step radioassay. Bio-Protocol, 10(7), e3581. (doi: 10.21769/BioProtoc.3581) (PMID:33659551) (PMCID:PMC7842805)

Blair, C. M. and Baillie, G. S. (2019) Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes. Biochemical Society Transactions, 47(5), pp. 1405-1414. (doi: 10.1042/BST20190252) (PMID:31506329)

Blair, C. M., Walsh, N., Littman, B. H., Marcoux, F. W. and Baillie, G. S. (2019) Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf. BMC Cancer, 19, 266. (doi: 10.1186/s12885-019-5489-4) (PMID:30909892) (PMCID:PMC6434832)

This list was generated on Tue Dec 7 08:26:11 2021 GMT.